OncoMatch/Clinical Trials/NCT06117774
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Is NCT06117774 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Tarlatamab for limited stage small cell lung cancer.
Treatment: Tarlatamab — The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage III
Excluded: Stage IV
Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy. Has completed chemoradiotherapy without progression per RECIST 1.1 (ie, achieved complete response [CR], partial response [PR], or stable disease [SD]).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: concurrent chemotherapy and radiotherapy — limited-stage SCLC
Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy. Has completed chemoradiotherapy without progression per RECIST 1.1 (ie, achieved complete response [CR], partial response [PR], or stable disease [SD]).
Cannot have received: sequential chemotherapy and thoracic radiotherapy
Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation.
Cannot have received: selective inhibitor of the delta-like ligand 3 (DLL3) pathway
Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
Cannot have received: immune-mediated therapy
Exception: severe or life-threatening events only
Prior history of severe or life-threatening events from any immune-mediated therapy.
Lab requirements
Blood counts
Adequate organ function.
Kidney function
Adequate organ function.
Liver function
Adequate organ function.
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Valkyrie Clinical Trials · Los Angeles, California
- University of California Los Angeles · Santa Monica, California
- Yale New Haven Hospital · New Haven, Connecticut
- Boca Raton Clinical Research Global South Florida · Plantation, Florida
- University of Louisville James Graham Brown Cancer Center · Louisville, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify